New drug may keep T-Cell lymphoma at bay after transplant
NCT ID NCT07356245
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphomas who are in remission after their transplant. Ruxolitinib works by calming the immune system and blocking signals that help cancer cells grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ruxolitinib
- What this could lead to
- If successful, this could offer a way to reduce the chance of T-cell lymphoma coming back and lower the risk of graft-versus-host disease after a stem cell transplant.
- What could go wrong
- This is a small, early-phase (phase II) study, so results may not apply to everyone. Ruxolitinib can cause side effects like low blood counts or infections, and it may not prevent relapse or GVHD in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Can a Five-Drug combo tame a tough lymphoma without standard chemo?
- Can a targeted antibody boost chemotherapy against a rare leukemia?
- Can a targeted pill boost Chemotherapy's punch against a rare lymphoma?
- A microchip implanted in tumors could reveal which drugs work best
- Engineered immune cells take aim at hard-to-treat blood cancers